AFO
APTO

Arrowroot Family Office’s Aptose Biosciences, Inc. APTO Stock Holding History

Arrowroot Family Office’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-149
Closed -$43K – 137
2023
Q1 		$43K Buy
+149
New +$43.3K 0.04% 116

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowroot Family Office's APTO Position: Q2 2023 in Review

Arrowroot Family Office sold out of Aptose Biosciences, Inc. (APTO) in Q2 2023, closing a stake of 149 shares — an estimated $43K sold.

Arrowroot Family Office first reported a position in APTO in Q1 2023 and held it in 1 quarter. The position peaked at $43K in Q1 2023. 24 funds tracked by Wall St. Rank hold APTO as of Q2 2023.

  • Arrowroot Family Office reported no remaining Aptose Biosciences, Inc. position as of Q2 2023 after selling out during the quarter.
  • Arrowroot Family Office sold 149 Aptose Biosciences, Inc. shares in Q2 2023, an estimated $43K.
  • Arrowroot Family Office first reported a position in Aptose Biosciences, Inc. in Q1 2023 and held it in 1 quarter.
  • Arrowroot Family Office's Aptose Biosciences, Inc. position peaked at $43K in Q1 2023.
  • 24 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2023.

Based on Arrowroot Family Office's 13F filing for Q2 2023, filed 17 Apr 2024.